Comparison between oral and intravenous fludarabine plus cyclophosphamide regime as front-line therapy in patients affected by chronic lymphocytic leukaemia: Influence of biological parameters on the clinical outcome

Annals of Hematology

Volumn 90, Issue 1, 2011, Pages 59-65

  Laurenti, Luca ^a   De Padua, Laura ^a   Tarnani, Michela ^a   Piccirillo, Nicola ^a   Falcucci, Paolo ^b   D'Arena, Giovanni ^c   Innocenti, Idanna ^a   Marietti, Sara ^a   Efremov, Dimitar G ^d   Chiusolo, Patrizia ^a   Zini, Gina ^a   Sora', Federica ^a   Sica, Simona ^a   Leone, Giuseppe ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b BELCOLLE HOSPITAL   (Italy)

^c Department of Radiology   (Italy)

^d ICGEB Outstation Monterotondo   (Italy)

Author keywords

Biological prognostic factors; Chronic lymphocytic leukaemia; Cyclophosphamide; Fludarabine

Indexed keywords

ACICLOVIR; CD38 ANTIGEN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN HEAVY CHAIN; PROTEIN KINASE ZAP 70; RITUXIMAB; STEROID;

ADULT; ADVANCED CANCER; AGE; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CHROMOSOME 11P; CHROMOSOME 17P; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; ERYTHROCYTE APLASIA; ERYTHROCYTE TRANSFUSION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HIGH RISK PATIENT; HUMAN; IMMUNE THROMBOCYTOPENIA; IMMUNOGLOBULIN VARIABLE REGION; INTERPHASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PURE RED CELL ANEMIA; PYREXIA IDIOPATHICA; RETREATMENT; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN TOXICITY; SUDDEN DEATH; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VIDARABINE;

EID: 78651301766     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-010-1025-y     Document Type: Article

References (18)

1. B Bellosillo N Villamor D Colomer G Pons E Montserrat J Gil 1999 In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia Blood 94 2836 2843 1:CAS:528:DyaK1MXmslantLo%3D 10515887
2. U Koehl L Li B Nowak 1997 Fludarabine and cyclophosphamide: synergistic cytotoxicity associated with inhibition of interstrand cross-link removal Proc Am Assoc Cancer Res 38 2, 10a
3. BF Eichhorst R Busch G Hopfinger 2006 Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia Blood 107 885 891 1:CAS:528:DC%2BD28Xht1OnsLc%3D 10.1182/blood-2005-06-2395 16219797 (Pubitemid 43156283)
4. D Catowsky S Richards E Matutes, et al. 2007 Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic laeukemia (the LRF CLL4 trial): a randomized controlled trial Lancet 370 230 239 10.1016/S0140-6736(07)61125-8 (Pubitemid 47069536)
5. S O'Brien HM Kantarjian J Cortes M Beran CA Koller FJ Giles, et al. 2001 Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia J Clin Oncol 19 1414 1420 11230486
6. IW Flinn DS Neuberg MR Grever GW Dewald JM Bennett EM Paietta, et al. 2007 Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US intergroup trial E2997 J Clin Oncol 25 7 793 798 1:CAS:528: DC%2BD2sXjvVKmt7c%3D 10.1200/JCO.2006.08.0762 17283364 (Pubitemid 350002879)
7. M Hallek G Fingerle-Rowson AM Fink, et al. 2009 First-line treatment with fludarabine (F), cyclophosphamide (C), and Rituximab (R) (FCR) improves overall survival in previously untreated patients with advanced chronic lymhocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international group of investigators and the german CLL study group Blood 114 22 abs 535
8. S Slilgenbauer T Zenz D Winkler, et al. 2008 Genomic aberrations, VH mutational status, and outcome after fludarabine and cyclophosphamide (FC) or FC plus Rituximab (FCR) in the CLL8 trial Blood 112 11 abs 781
9. T Robak A Dmoszynska P Solal-Céligny, et al. 2010 Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia J Clin Oncol 28 10 1756 1765 1:CAS:528:DC%2BC3cXmtVyhurc%3D 10.1200/JCO.2009.26.4556 20194844
10. BD Cheson JM Bennet M Grever N Kay MJ Keating S O'Brien, et al. 1996 National cancer institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment Blood 87 12 4990 4997 1:CAS:528:DyaK28XjsFGisb8%3D 8652811
11. M Hallek BD Cheson D Catovsky, et al. 2008 Guidelines for the diagnosis and treatment of chronic lymphocytic leucemia: a report from the international workshop on chronic lymphocytic leukemia updating the national cancer institute-working group 1996 guidelines Blood 111 12 5446 5456 1:CAS:528:DC%2BD1cXnsVOktrk%3D 10.1182/blood-2007-06-093906 18216293
12. L Laurenti M Tarnani L De Padua, et al. 2008 Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration Ann Hematol 87 891 898 1:CAS:528:DC%2BD1cXhtFKlsrnJ 10.1007/s00277-008-0527-3 18587576
13. H Dohner S Stilgenbauer A Benner, et al. 2000 Genomic aberration and survival in chronic lymphocytic leukemia N Engl J Med 343 1910 1916 1:CAS:528:DC%2BD3MXktlSlsQ%3D%3D 10.1056/NEJM200012283432602 11136261 (Pubitemid 32064784)
14. M Ivanovski F Silvestri G Pozzato, et al. 1998 Somatic hypermutation, clonal diversity, and preferential expression of the VH 51p1/VL kv325 immunoglobulin gene combination in hepatitis C virus-associated immunocytomas Blood 91 2433 2442 1:CAS:528:DyaK1cXitF2hsL4%3D 9516143
15. M Crespo F Bosh N Villamor B Bellosillo D Colomer M Rozman 2003 ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia N Engl J Med 348 18 1764 1775 1:CAS:528: DC%2BD3sXjtlWqsro%3D 10.1056/NEJMoa023143 12724482 (Pubitemid 36514707)
16. RN Damle T Wasil F Fais, et al. 1999 Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia Blood 94 1840 1847 1:CAS:528:DyaK1MXlvFCnur0%3D 10477712
17. B Cazin M Divine S Lepretre P Travade, et al. 2008 High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia Br J Hematol 143 54 59 1:CAS:528:DC%2BD1cXht1ClsL%2FM 10.1111/j.1365-2141.2008.07309.x
18. CS Tam S O'Brien W Wierda, et al. 2008 Long-term results of the fludarabine, cyclophosphamide, and Rituximab regimen as initial therapy of chronic lymphocytic leukemia Blood 112 975 980 1:CAS:528:DC%2BD1cXpvVOks7c%3D 10.1182/blood-2008-02-140582 18411418